Exclusive Summary

• - Fully off-patent, guideline-driven and multi-setting use (VTE, PCI/ACS, dialysis, ECMO/CPB) ensures stable, hospitalization-linked demand.
• - Multi-pharmacopoeia compliance (USP/EP/BP/Ph.Int./KP) plus versatile strengths (5.0ml/5000IU; 5.0ml/25000IU) enable broad registrations and tender readiness.
• - Large addressable need: ~10M VTE cases/year, ~4–5M PCI/year, and ~3.8–4.0M dialysis patients generating >600M sessions/year are core heparin consumption drivers.
• - Strong clinical positioning: on WHO Essential Medicines List; major guidelines prefer UFH in renal impairment, rapid reversal, and ECMO/CPB/PCI settings.
• - Cost and supply-chain differentiation: typically 30–70% below legacy brands and much cheaper than LMWH per treatment day; traceable animal-origin supply and stringent QC are decisive for buyers.